Posted by Michael Wonder on 13 Jan 2025
International collaboration provides new guidance on the use of surrogate endpoints in cost effectiveness analysis
9 January 2025 - Recommendations will help organisations that appraise new drugs establish whether their use will result in longer-term benefits for patients.
Four health technology assessment agencies, including Canada’s Drug Agency, have published new guidance on the use of surrogate endpoints in cost effectiveness analysis to inform decision-making when evaluating new medicines.
